GH Research PLC (GHRS)

11,99 0,00 (0,00%) Al cierre: 04:00PM EDT

GH Research PLC

Joshua Dawson House
Dawson Street
Dublin D02 RY95
Ireland
353 1 437 8334
https://www.ghres.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 49

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Florian Schonharting M.Sc. (Econ)	Co-Founder & Non-Executive Chairman of the Board	N/A	N/A	1969
Dr. Theis Terwey M.D.	Co-Founder & CEO	N/A	N/A	1976
Mr. Magnus Halle	Co-Founder & MD of Ireland	N/A	N/A	1997
Ms. Julie Ryan F.C.A.	Vice President of Finance	N/A	N/A	1986
Mr. Aaron Cameron M.B.A.	Chief Operating Officer	N/A	N/A	1985
Mr. Naoise Gaffney	VP & Head of Intellectual Property	N/A	N/A	N/A
Dr. Velichka Valcheva M.D.	Chief Medical Officer	N/A	N/A	1975

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Gobierno corporativo

El ISS Governance QualityScore de GH Research PLC, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.